ARFONAD
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARFONAD is an injectable small-molecule drug approved in 1954 by Roche. The generic name and mechanism of action are not disclosed in available data. This legacy product represents a significant historical pharmaceutical asset.
LOE Approaching
Product is approaching loss of exclusivity with minimal reported commercial activity, suggesting a small team focused on maintenance and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ARFONAD offers limited career growth due to its LOE-approaching status and minimal job pipeline. Roles focus on legacy management, compliance, and transition planning rather than innovation or market expansion.
Product ManagerMedical Science Liaison
Worked on ARFONAD at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.